Re: Le biais de mauvaise catégorisation

Paul Aubrin a formulé la demande :

Le 16/06/2025 à 00:09, Every.body a écrit :

C'est pourtant l'usage pour tous les vaccins: il faut un certain délai
pour que l'immunité soit acquise.

 Sans doute, mais comme celui-là est censé tuer le patient, ils veulent compter les vaccinés dès l'injection. Pas de panique, il y a des survivants ?

>
Pour évaluer le rapport bénéfice/risque complet, il faut comparer un échantillon représentatif qui a reçu le traitement à que échantillon représentation qui ne l'a pas reçu.

https://pubmed.ncbi.nlm.nih.gov/?term=covid19+vaccine+placebo&page=1
prenons la première
Results: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with PLACEBO. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to PLACEBO; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in PLACEBO recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and PLACEBO groups.
hop, pas besoin de dire merci
--
Bruno
L’exemple est la preuve des cons.
[Richard sur Terre]